Bernstein analyst Lee Hambright upgrades $Edwards Lifesciences (EW.US)$ to a hold rating.
According to TipRanks data, the analyst has a success rate of 70.0% and a total average return of 11.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
Edwards Lifesciences experienced a strong performance in terms of sales and earnings, and the forward-looking guidance for Q4, along with future projections up to 2025, are anticipated to sustain the stock's upward trajectory.
The expectation is that it will require several more quarters for Edwards Lifesciences to demonstrate to investors that the lowest point has been reached for its TAVR franchise following the Q3 report.
Expectations were moderate prior to the quarterly results, and the commentary for the third quarter, fourth quarter, and future fiscal year did not strongly suggest that risks had been fully accounted for. Although the deceleration in fourth quarter Transcatheter Aortic Valve Replacement (TAVR) trends may be due to some one-time factors, it remains challenging to counter the possibility that TAVR growth may continue to slow down in the coming fiscal year.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
聯博集團分析師Lee Hambright上調$愛德華生命科學 (EW.US)$至持有評級。
根據TipRanks數據顯示，該分析師近一年總勝率為70.0%，總平均回報率為11.9%。
此外，綜合報道，$愛德華生命科學 (EW.US)$近期主要分析師觀點如下：
愛德華生命科學在銷售和收益方面取得了強勁表現，以及對第四季度的前瞻展望，以及未來到2025年的預測，有望維持股票的上升軌跡。
預期愛德華生命科學需要幾個季度時間向投資者證明其TAVR特許經營權在Q3報告後已經觸底。
在季度業績公佈之前，市場對愛德華生命科學的預期較爲溫和，而第三季度、第四季度和未來財年的評論並未強烈暗示風險已被充分考慮在內。儘管第四季度經皮主動脈瓣置換（TAVR）的增長速度放緩可能是由於一些一次性因素，但要應對TAVR增長可能在未來財年繼續放緩的可能性仍具有挑戰性。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
